Cytotoxic T-lymphocyte Associated Protein 4 (CTLA-4) is an immune checkpoint molecule highly expressed on regulatory T-cells (Tregs) that can inhibit the activation of effector T-cells. Anti-CTLA-4 therapy can confer long-lasting clinical benefits in cancer patients as a single agent or in combination with other immunotherapy agents. However, patient response rates to anti-CTLA-4 are relatively low, and a high percentage of patients experience severe immune-related adverse events. Clinical use of anti-CTLA-4 has regained interest in recent years; however, the mechanism(s) of anti-CTLA-4 is not well understood. Although activating T-cells is regarded as the primary anti-tumor mechanism of anti-CTLA-4 therapies, mounting evidence in the literature suggests targeting intra-tumoral Tregs as the primary mechanism of action of these agents. Tregs in the tumor microenvironment can suppress the host anti-tumor immune responses through several cell contact-dependent and -independent mechanisms. Anti-CTLA-4 therapy can enhance the priming of T-cells by blockading CD80/86-CTLA-4 interactions or depleting Tregs through antibody-dependent cellular cytotoxicity and phagocytosis. This review will discuss proposed fundamental mechanisms of anti-CTLA-4 therapy, novel uses of anti-CTLA-4 in cancer treatment and approaches to improve the therapeutic efficacy of anti-CTLA-4.
Tumor-specific CD8+ T cells are critical components of antitumor immunity; however, factors that modulate their phenotype and function have not been completely elucidated. Cytokines IL-12 and IL-27 have recognized roles in promoting CD8+ T cells’ effector function and mediated antitumor responses. Tumor-specific CD8+ tumor-infiltrating lymphocytes (TILs) can be identified based on surface expression of CD39, whereas bystander CD8+ TILs do not express this enzyme. It is currently unclear how and why tumor-specific CD8+ T cells uniquely express CD39. Given the important roles of IL-12 and IL-27 in promoting CD8+ T cell functionality, we investigated whether these cytokines could modulate CD39 expression on these cells. Using in vitro stimulation assays, we identified that murine splenic CD8+ T cells differentially upregulate CD39 in the presence of IL-12 and IL-27. Subsequently, we assessed the exhaustion profile of IL-12– and IL-27–induced CD39+CD8+ T cells. Despite the greatest frequency of exhausted CD39+CD8+ T cells after activation with IL-12, as demonstrated by the coexpression of TIM-3+PD-1+LAG-3+ and reduced degranulation capacity, these cells retained the ability to produce IFN-γ. IL-27–induced CD39+CD8+ T cells expressed PD-1 but did not exhibit a terminally exhausted phenotype. IL-27 was able to attenuate IL-12–mediated inhibitory receptor expression on CD39+CD8+ T cells but did not rescue degranulation ability. Using an immunogenic neuro-2a mouse model, inhibiting IL-12 activity reduced CD39+CD8+ TIL frequency compared with controls without changing the overall CD8+ TIL frequency. These results provide insight into immune regulators of CD39 expression on CD8+ T cells and further highlight the differential impact of CD39-inducing factors on the phenotype and effector functions of CD8+ T cells.
Background Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) highly expressed on regulatory T-cells (Tregs) inhibit the activation of pro-inflammatory T-cells responsible for eliminating cancer cells. Anti-CTLA-4 can enhance T-cell activation by increasing CD28 co-stimulatory signaling through CTLA-4 blockade or depletion of Tregs by Fc-dependent effector mechanisms. Strategies to improve its therapeutic efficacy are needed as patient response rates to anti-CTLA-4 are low. Response to anti-CTLA-4 has been positively correlated with tumor mutation burden (TMB). Defects in the DNA mismatch repair (MMR) pathway can increase TMB and the production of neoantigens that promote anti-tumor immune responses.Here we investigate the underlying mechanism(s) to which induced MMR deficiency in an immunologically-cold and low TMB tumor model can enhance the therapeutic effect of anti-CTLA-4. We hypothesize that induced MMR deficiency in tumors enhances anti-CTLA-4-mediated Treg depletion and increases the infiltration and activation of effector T-cells. Methods MMR deficiency was induced in a syngeneic murine neuro-2a neuroblastoma cell line by knocking-out MLH1 expression using CRISPR-Cas9. Wildtype MMR-proficient (pMMR) or induced MMR-deficient (idMMR) neuro-2a cells were inoculated into immunocompetent A/J mice and treated with anti-CTLA-4. Tumors were immunophenotyped by flow cytometry and mixed-lymphocyte reaction assays were used to examine the effects of MMR deficiency and anti-CTLA-4 on T-cell activation and proliferation. Results Induced MMR deficiency in neuroblastoma tumors enhances the anti-tumor immune response induced by anti-CTLA-4. MMR deficiency in neuroblastoma tumors promoted anti-CTLA-4-mediated Treg depletion and increased intratumoral CD3 + T-cells. idMMR neuroblastoma tumors had an increase of ICOS + T-cells compared to pMMR tumors. In addition, ICOS + T-cells were increased further with anti-CTLA-4 treatment. Conclusions Our data show that inducing MMR deficiency in low TMB and immune-cold neuroblastoma tumors can enhance the anti-tumor effect of anti-CTLA-4 by increasing Tcell activation and depletion of Tregs. By understanding the underlying mechanism(s) of anti-CTLA-4 in idMMR tumors, it may justify targeting the MMR pathway to improve the response to immune checkpoint inhibitors in patients with immunologically-cold and/or low TMB tumors that are refractory to immunotherapy. Future studies will assess how inducing MMR deficiency alters the tumor microenvironment to enable anti-CTLA-4-mediated Treg depletion and the significance of ICOS + T-cells in the efficacy of anti-CTLA-4 therapy in this setting.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.